Search

EHA2024 Hybrid Congress

Thank you all for joining us in Madrid for the 29th European Hematology Association Congress!

The EHA2024 Congress platform is now closed. You may browse selected content through the EHA Library, EHA Open access library.

Read more

EHA-SLCH Hematology Tutorial on Hematological Disorders

Date: March 18-19, 2022

Format: Hybrid

EHA and the Sri Lanka College of Haematologists (SLCH) are happy to have successfully organized the EHA-SLCH Hematology Tutorial on Hematological Disorders on March 18 and 19, 2022.

Read more

EHA Research Grant review and selection process

1. Eligibility checkAfter the deadline has passed, we'll check your application for completion and compliance with the eligibility criteria.

Read more

Borderless careers

Start enriching your professional journey with EHA todayAdvance your career at any stage with the European Hematology Association.

Read more

Reducing bureaucracy in clinical trials: now is the time!

Medical societies and patient advocates across disciplines have joined forces with EHA to call for urgent action to make clinical trials less bureaucratic and more patient-centered, efficient and cheaper.

Read more

Does the patient with myelofibrosis feel better through Pacritinib?

Pacritinib is an oral next-generation multikinase inhibitor with specificity for JAK2 and FLT3 being evaluated to treat myelofibrosis in two Phase 3 trials.

Read more

More than science: the European Affairs program at EHA2023

To develop and administer safe, innovative and effective treatments for patients with blood diseases, hematologists need an effective and enabling regulatory environment.

Read more

Third ‘i4MDS’ consortium general meeting held in The Hague

Mar 17 2025 Posted in Meeting reports Tagged i4MDS

The International Integrative Innovative Immunology for Myelodysplastic Neoplasms ('i4MDS') consortium held its third general meeting in The Hague from February 7–8, 2025.

Read more

CAR NK-cells project, February 2025 update

A project update from Dr Ciprian Tomuleasa. We successfully designed and tested in vitro CAR T and CAR NK cells, transfected with the iCas9 suicide trigger.

Read more